Form 4: Eli Lilly Director Acquires 20 Shares Through Deferral Plan

Director Juan R. Luciano acquired 20 shares of Eli Lilly stock through a deferral plan, at a price of $750.77 per share.

Summary

• Juan R. Luciano, a director at Eli Lilly & Co, acquired 20 shares of common stock on April 15, 2024.
• The shares were acquired at a price of $750.77 each.
• This acquisition was made through the Lilly Directors' Deferral Plan, where stock units are deferred in lieu of cash compensation.
• The shares will be settled in common stock after Mr. Luciano's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally neutral to positive as it shows director confidence. The sentiment is not overly positive or negative.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to insider transactions, which are common in publicly traded companies. It reflects a director's participation in a company deferral plan.

Comparison to Industry Standards

• Director stock acquisitions are a common practice across publicly listed companies, often as part of compensation or deferral plans.
• The use of deferral plans is a standard method for aligning director interests with long-term shareholder value.
• The price of $750.77 per share is specific to Eli Lilly's stock at the time of the transaction and would be compared to other pharmaceutical companies' stock prices at the same time.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows director confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Stock Acquisition, Deferral Plan, Form 4, Insider Trading, Share Transaction